Pro-oncogenic, intra host viral quasispecies in Diffuse large B cell lymphoma patients with occult Hepatitis B Virus infection.
Adult
Aged
Aged, 80 and over
DNA, Viral
/ genetics
Genetic Variation
Hepatitis B
/ complications
Hepatitis B Surface Antigens
/ genetics
Hepatitis B virus
/ classification
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Lymphoma, Large B-Cell, Diffuse
/ virology
Middle Aged
Mutation, Missense
Prospective Studies
Quasispecies
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 10 2019
10 10 2019
Historique:
received:
19
11
2018
accepted:
26
09
2019
entrez:
12
10
2019
pubmed:
12
10
2019
medline:
12
11
2020
Statut:
epublish
Résumé
Non Hodgkin lymphoma, predominantly Diffuse Large B-cell Lymphoma (DLBCL) has been reported to have a significant association with Hepatitis B virus (HBV). We investigated the presence of different gene segments of HBV in plasma, B-cells and tumor tissues from DLBCL patients and explored the genetic variability of HBV within and across different compartments in a host using Next Generation Sequencing. Despite all 40 patients being HBV seronegative, 68% showed evidence of occult HBV. Sequencing of these gene segments revealed inter-compartment viral variants in 26% of them, each with at least one non-synonymous mutation. Between compartments, core gene variants revealed Arg94Leu, Glu86Arg and Ser41Thr while X gene variants revealed Phe73Val, Ala44Val, Ser146Ala and Ser147Pro. In tumor compartments per se, several mis-sense mutations were detected, notably the classic T1762A/A1764G mutation in the basal core promoter. In addition, a virus surface antigen mis-sense mutation resulting in M125T was detected in all the samples and could account for surface antigen negativity and occult HBV status. It would be interesting to further explore if a temporal accumulation of viral variants within a favored niche, like patients' lymphocytes, could bestow survival advantage to the virus, and if certain pro-oncogenic HBV variants could drive lymphomagenesis in DLBCL.
Identifiants
pubmed: 31601912
doi: 10.1038/s41598-019-51157-1
pii: 10.1038/s41598-019-51157-1
pmc: PMC6787061
doi:
Substances chimiques
DNA, Viral
0
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14516Références
Sci Rep. 2016 Jul 27;6:30374
pubmed: 27461034
Dig Dis Sci. 2015 May;60(5):1315-24
pubmed: 25567052
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:123-30
pubmed: 21199523
World J Gastroenterol. 2014 Jun 28;20(24):7653-64
pubmed: 24976703
Intern Med J. 2010 Sep;40(9):633-41
pubmed: 19811561
J Clin Microbiol. 2015 Jun;53(6):1831-5
pubmed: 25788548
Gastroenterology. 2004 Jan;126(1):102-10
pubmed: 14699492
World J Hepatol. 2015 Nov 28;7(27):2729-39
pubmed: 26644816
Clin Vaccine Immunol. 2011 Jun;18(6):914-21
pubmed: 21490166
Jundishapur J Microbiol. 2015 Nov 21;8(11):e25726
pubmed: 26862382
Clin Res Hepatol Gastroenterol. 2013 Sep;37(4):373-83
pubmed: 23477988
FEMS Microbiol Lett. 1999 May 15;174(2):247-50
pubmed: 10339815
Lancet Oncol. 2010 Sep;11(9):827-34
pubmed: 20688564
J Med Virol. 2016 Dec;88(12):2206-2210
pubmed: 27219865
Am J Blood Res. 2012;2(1):18-28
pubmed: 22432084
Oncogene. 2007 Apr 2;26(15):2166-76
pubmed: 17401425
J Virol. 2009 Oct;83(19):9983-92
pubmed: 19420079
J Virol. 1989 Nov;63(11):4645-52
pubmed: 2677399
Ann Hematol. 2008 Jun;87(6):475-80
pubmed: 18327583
J Med Virol. 2010 Jul;82(7):1115-25
pubmed: 20513073
Med Oncol. 2010 Jun;27(2):310-8
pubmed: 19350421
Egypt J Immunol. 2006;13(1):105-14
pubmed: 17974155
Pathog Glob Health. 2016 Oct - Dec;110(7-8):287-291
pubmed: 27788631
Hepatology. 2007 Jul;46(1):107-12
pubmed: 17526021
World J Gastroenterol. 2016 Apr 7;22(13):3531-46
pubmed: 27053845
Bioinformatics. 2011 Nov 1;27(21):2987-93
pubmed: 21903627
J Egypt Natl Canc Inst. 2015 Mar;27(1):11-8
pubmed: 25716703
Immunol Rev. 2000 Apr;174:98-111
pubmed: 10807510
World J Gastroenterol. 2007 Jan 7;13(1):74-81
pubmed: 17206756
World J Hepatol. 2015 May 18;7(8):1086-96
pubmed: 26052397
Microbiol Mol Biol Rev. 2012 Jun;76(2):159-216
pubmed: 22688811
J Med Virol. 2014 Jan;86(1):156-61
pubmed: 24132580
Virol J. 2010 Aug 27;7:204
pubmed: 20799931
PLoS One. 2014 Oct 15;9(10):e110012
pubmed: 25333524
Clin Microbiol Rev. 2012 Jan;25(1):142-63
pubmed: 22232374
Br J Cancer. 2014 Feb 18;110(4):1066-73
pubmed: 24346287
J Virol. 2004 Jul;78(14):7575-81
pubmed: 15220432
J Cancer Res Clin Oncol. 2012 Dec;138(12):1993-2001
pubmed: 22767316
J Med Virol. 2017 Oct;89(10):1796-1803
pubmed: 28513915
Hepatology. 2000 Jul;32(1):116-23
pubmed: 10869298
Eur J Cancer Prev. 2012 May;21(3):261-7
pubmed: 22433629